Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $51.2 million.

  • Ani Pharmaceuticals' Accumulated Expenses rose 72.10% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 72.10%. This contributed to the annual value of $37.7 million for FY2024, which is 58.60% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Accumulated Expenses stood at $51.2 million for Q3 2025, which was up 42.23% from $36.0 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Accumulated Expenses peaked at $51.2 million during Q3 2025, and registered a low of $4.9 million during Q3 2021.
  • In the last 3 years, Ani Pharmaceuticals' Accumulated Expenses had a median value of $23.7 million in 2025 and averaged $25.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first dropped by 19.63% in 2021, then surged by 130.66% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $8.5 million in 2021, then grew by 21.00% to $10.3 million in 2022, then spiked by 130.66% to $23.8 million in 2023, then soared by 58.60% to $37.7 million in 2024, then skyrocketed by 72.10% to $51.2 million in 2025.
  • Its Accumulated Expenses was $51.2 million in Q3 2025, compared to $36.0 million in Q2 2025 and $23.7 million in Q1 2025.